Results(4564)
The SIGMA Consortium (SIGMA)
Denmark
European Union
France
Germany
Italy
Netherlands
Norway
Spain
Sweden
United Kingdom
First published:
19/01/2026
Network
ENCePP partner
CABFIDENCE: Global Real-World Evidence Cohort Study to evaluate Utilization, Clinical and Patient-Reported Outcomes among CAB+RPV LA users (224047)
Australia
Canada
France
Germany
Italy
Japan
Korea, Republic of
Portugal
Spain
Taiwan
United Kingdom
United States
EU PAS number:
EUPAS1000000616
First published:
19/01/2026
Study
Ongoing
Real-world Evidence on Diagnosed Gastroparesis in Europe: Multi-database Observational Epidemiological Study (TAK-906-5003)
Finland
Spain
EU PAS number:
EUPAS37806
First published:
19/01/2026
Study
Finalised
Evaluating the Effectiveness of Eliquis® Additional Risk Minimization Measures in Kingdom of Saudi Arabia.
Saudi Arabia
EU PAS number:
EUPAS1000000270
First published:
19/01/2026
Study
Ongoing
An Immuno-Dermatological disease registry to understand the burden of Atopic dermatitis (AD), Alopecia areata (AA), and Vitiligo in Indian Patients
India
EU PAS number:
EUPAS48566
First published:
19/01/2026
Study
Ongoing
Post-marketing study to assess the risk of intussusception after immunization with GlaxoSmithKline (GSK) Biologicals’ oral live-attenuated human rotavirus vaccine in infants less than 1 year old in Latin America (212329)
Argentina
Colombia
Dominican Republic
Honduras
Mexico
Panama
EU PAS number:
EUPAS1000000701
First published:
19/01/2026
Study
Ongoing
Vedolizumab-4081: Infection Outcomes among Advanced Therapy-naive Older Adult US Patients With UC/CD Initiating ENTYVIO, TNF-alpha Inhibitors, or Ustekinumab: A Retrospective Observational Matched-Cohort Study Using Medicare Claims Data, 2016-2025
United States
EU PAS number:
EUPAS1000000767
First published:
19/01/2026
Study
Ongoing
A Non-interventional, Post-authorization Safety Study of Patients with Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden (CC-5013-MCL-005)
Austria
France
Germany
Greece
Italy
Netherlands
Spain
EU PAS number:
EUPAS23366
First published:
19/01/2026
Study
Finalised
Interstitial Lung Disease management across Germany: A nationwide, cross-sectional survey among pulmonologists and rheumatologists to evaluate possible differences in regional and intersectoral care (CareILD)
Germany
EU PAS number:
EUPAS1000000871
First published:
19/01/2026
Study
Planned
Postmarketing Surveillance Study of EVENITY (Romosozumab) in South Korea (20170753)
Korea, Republic of
EU PAS number:
EUPAS30346
First published:
16/01/2026
Study
Finalised
Real-world post-authorization effectiveness study (PAES) of pembrolizumab for the treatment of NSCLC across races, ethnicities, and age groups (MK-3475-G18)
United States
EU PAS number:
EUPAS1000000576
First published:
16/01/2026
Study
Ongoing
Health Impact - Swedish Population Evidence Enabling Data-linkage
First published:
16/01/2026
Sweden
Data source
Human
Birth registry
Cancer registry
Death registry
Disease registry
Drug registry
Hospital discharge records
Hospital inpatient records
Hospital outpatient visit records
Population registry
Primary care medical records
Vaccination registry
Big Multiple Sclerosis Data (BMSD) Network
Australia
Czechia
Denmark
France
Italy
Sweden
First published:
16/01/2026
Network
Retrospective, non-interventional, multicenter study on the effectiveness and safety of QUVIVIQ in patients with insomnia disorder and comorbid restless legs syndrome.
Austria
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000859
First published:
16/01/2026
Study
Planned
Rivaroxaban real world effectiveness in patients with atrial fibrillation (GUARDIAN)
Bosnia and Herzegovina
Serbia
EU PAS number:
EUPAS1000000869
First published:
15/01/2026
Study
Finalised
Cariprazine in patients with schizophrenia – real-life data analysis based on the NEAK database (HU-NIS-CARIPRAZINE-01/2024)
Hungary
EU PAS number:
EUPAS1000000422
First published:
15/01/2026
Study
Finalised
TAK-755-4007: A Post-Authorization Safety Study (PASS) to Further Evaluate Real-World Safety in Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated with Adzynma
Austria
France
Germany
Italy
Poland
Spain
Switzerland
United Kingdom
EU PAS number:
EUPAS1000000870
First published:
14/01/2026
Study
Planned
A post-marketing database surveillance to investigate the risk of diagnosed myelosuppression events in MRSA patients treated with tedizolid or linezolid in Japan (MK-1986-045)
Japan
EU PAS number:
EUPAS1000000896
First published:
14/01/2026
Study
Ongoing
Observational study to assess effectiveness of ROTATEQ® against acute gastroenteritis (AGE) due to rotavirus (regardless of type) and by type in China
China
EU PAS number:
EUPAS1000000734
First published:
14/01/2026
Study
Ongoing
Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma
United States
EU PAS number:
EUPAS1000000513
First published:
14/01/2026
Study
Ongoing
A post-marketing database surveillance to investigate the risk of diagnosed lactic acidosis events in MRSA patients treated with tedizolid or linezolid in Japan (MK-1986-046)
Japan
EU PAS number:
EUPAS1000000894
First published:
14/01/2026
Study
Ongoing
A post-marketing database surveillance to investigate the risk of diagnosed peripheral neuropathy and optic nerve disorder events in MRSA patients treated with tedizolid or linezolid in Japan (MK-1986-047)
Japan
EU PAS number:
EUPAS1000000898
First published:
14/01/2026
Study
Ongoing
A regulatory required non interventional study to monitor the safety and effectiveness of once daily treatment of orally inhaled Vahelva Respimat (Tiotropium + Olodaterol fixed dose combination 2.5µg/2.5µg per puff (2 puffs comprise one medicinal dose)) for Korean patients with COPD (Chronic Obstructive Pulmonary Disease) (Vahelva Respimat regulatory Post-marketing Surveil)
Korea, Republic of
EU PAS number:
EUPAS14956
First published:
14/01/2026
Study
Finalised
I8F-MC-B016 Tirzepatide Pregnancy Registry - A Multi-Country Registry-Based Observational Study to Assess Maternal, Fetal, and Infant Outcomes Following Treatment with Tirzepatide for Weight Management During Pregnancy
Germany
United Kingdom
United States
EU PAS number:
EUPAS1000000517
First published:
14/01/2026
Study
Planned
209452 - A targeted safety study, EPI-ZOSTER-030 VS US DB, to evaluate the safety of Shingrix in adults ≥ 50 years of age in the United States
United States
EU PAS number:
EUPAS37156
First published:
14/01/2026
Study
Ongoing
Effectiveness of ROTATEQ® when administered with intervals greater than 10 weeks between doses in Chinese children: an observational study of V260-077 study participants with longer dosing interval (V260-080)
China
EU PAS number:
EUPAS1000000730
First published:
14/01/2026
Study
Ongoing
Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Australia
Korea, Republic of
United States
EU PAS number:
EUPAS1000000551
First published:
14/01/2026
Study
Ongoing
A multicenter evaluation of the treatment persistence of advanced therapies (Biological disease-modifying agents and Targeted synthetic Disease Modifying Anti-Rheumatic Drugs) in the treatment of rheumatoid arthritis (RA): A Real World Evidence (RWE) study from India
India
EU PAS number:
EUPAS103727
First published:
12/01/2026
Study
Ongoing
Prospective, multi-country, observational registry to collect clinical
Austria
Croatia
Czechia
France
Germany
Italy
Netherlands
Portugal
Spain
Sweden
EU PAS number:
EUPAS21731
First published:
12/01/2026
Study
Ongoing
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD)
Austria
France
Germany
Italy
Poland
Spain
Sweden
United Kingdom
United States
EU PAS number:
EUPAS7708
First published:
12/01/2026
Study
Ongoing
A Retrospective Cohort Study Using Health Administrative Claims Databases to Assess Adverse Pregnancy and Infant Outcomes in Women with Psoriasis Who Were Exposed to Guselkumab Versus Other Biologic Therapies During Pregnancy. PASS-EMA
United States
EU PAS number:
EUPAS30740
First published:
12/01/2026
Study
Ongoing
Cohort Event Monitoring of safety of COVID-19 vaccines in special populations (pregnant and lactating women, children and adolescents, immunocompromised, people with history of allergy, people with prior SARS-CoV-2 infection) (Covid-Vaccine-Monitor CVM)
Belgium
Croatia
France
Germany
Ireland
Italy
Netherlands
Portugal
Romania
Slovakia
Spain
Switzerland
United Kingdom
EU PAS number:
EUPAS42504
First published:
12/01/2026
Study
Finalised
EVALUATION OF THE EFFECTIVENESS OF THE ADDITIONAL RISK MINIMISATION MEASURES FOR GLOFITAMAB: A PASS SURVEY AMONG HEALTHCARE PROFESSIONALS IN EUROPEAN COUNTRIES
Austria
Belgium
Bulgaria
Croatia
France
Germany
Greece
Italy
Norway
Portugal
Sweden
EU PAS number:
EUPAS1000000863
First published:
12/01/2026
Study
Planned
Epidemiological study of epilepsy in France based on two databases (Epi²)
France
EU PAS number:
EUPAS1000000899
First published:
09/01/2026
Study
Ongoing
A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
Austria
Brazil
Germany
United States
EU PAS number:
EUPAS49218
First published:
09/01/2026
Study
Ongoing
RIOJA SALUD
First published:
09/01/2026
Spain
Data source
Human
Other
Population registry
Registration with healthcare system
The carbon footprint of pharmaceuticals for diabetes and cardiovascular diseases
Denmark
EU PAS number:
EUPAS1000000641
First published:
09/01/2026
Study
Ongoing
Therapy of metastatic castration-resistant prostate cancer with Talazoparib + Enzalutamide under real world conditions in Germany – an observational medical chart review study (PROTEGE study)
Germany
EU PAS number:
EUPAS1000000593
First published:
09/01/2026
Study
Ongoing
Long-term, observational cohort study of adults with plaque psoriasis (PsO), who are new users of deucravacitinib, tumour necrosis factor inhibitor (TNFi) biologics, non-TNFi biologics, or non-biologic therapies in the real-world clinical setting
Denmark
Finland
France
Germany
Norway
Spain
EU PAS number:
EUPAS1000000659
First published:
09/01/2026
Study
Planned
Compare data sources